771 completed, 399 unknown, 121 recruiting, 72 not yet recruiting. 641 Not applicable, 199 Phase 4, 172 Phase 2, 43 Phase 3, 42 Phase 1.
Follow Yonsei University: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dapagliflozin in Patients With Non-Obstructive Hypertrophic Cardiomyopathy: A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Dapagliflozin 10mg, Dapagliflozin Placebo - Nonobstructive Hypertrophic Cardiomyopathy | Phase 4 | Not yet recruiting | Yonsei University | 440 | 2027-01-02 | 2026-10-27 |
| Disease-modifying Efficacy of Sitagliptin Therapy in Early-stage Parkinson's Disease Sitagliptin, Sitagliptin placebo - Parkinson Disease | Phase 2 | Not yet recruiting | Yonsei University | 160 | 2026-12-15 | 2026-09-10 |
| Feasibility of Combination Therapy With Low-dose Statin and Ezetimibe in Patients With Minimal Subclinical Atherosclerosis Crezet 2.5/10mg, Litorvazet 5/10mg, Baroezet 1/10mg - Atherosclerosis Cardiovascular Disease | Phase 4 | Not yet recruiting | Yonsei University | 300 | 2026-11-10 | 2026-10-16 |
| Efficacy and Safety of the Angionix Balloon in Patients With Coronary Artery Disease Undergoing PTCA Angionix Balloon - Coronary Artery Disease | Not yet recruiting | Yonsei University | 600 | 2026-11-09 | 2026-10-09 | |
| Lenvatinib in Patients With Advanced Parathyroid Carcinoma Lenvatinib - Parathyroid Carcinoma | Phase 2 | Not yet recruiting | Yonsei University | 18 | 2026-11-01 | 2026-09-28 |
| Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer Lurbinectedin, Paclitaxel - Carcinoma, Small Cell Lung | Phase 2 | Not yet recruiting | Yonsei University | 69 | 2026-11-01 | 2026-09-04 |
| Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Combination Therapy With Pembrolizumab and Irinotecan in Patients With Metastatic or Recurrent Malignant Melanoma Pembrolizumab and Irinotecan - Unresectable or Metastatic Melanoma | Phase 1 / Phase 2 | Not yet recruiting | Yonsei University | 46 | 2026-11-01 | 2026-09-14 |
| SVF Cellular Composition, Secretome, and Responses in Knee Osteoarthritis Autologous adipose-derived stromal vascular fraction intra-articular injection - Osteoarthritis, Knee | Recruiting | Yonsei University | 20 | 2026-11-01 | 2026-10-27 | |
| Clinical and Biological Outcomes of BioBrace-Augmented ACL Reconstruction BioBrace® Reinforced BioInductive Implant - Anterior Cruciate Ligament Injuries, Anterior Cruciate Ligament Rupture | Not applicable | Not yet recruiting | Yonsei University | 30 | 2026-11-01 | 2026-10-30 |
| An Intervention to Reduce Sedentary Behavior and Promote Physical Activity in Colorectal Cancer Chemotherapy Sedentary behavior reduction intervention for patients with colorectal cancer undergoing chemotherapy - Colorectal Neoplasms, Sedentary Behavior | Not applicable | Not yet recruiting | Yonsei University | 40 | 2026-10-01 | 2026-09-29 |
| A Phase 2 Multicenter Single-Arm Clinical Trial of Zanzalintinib and Pembrolizumab in Subjects With Resectable Clear Cell Renal Cell Carcinoma Zanzalintinib and Pembrolizumab - Patients With Locally Advanced or Metastatic But Resectable Clear Cell Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Yonsei University | 48 | 2026-10-01 | 2026-07-09 |
| Procedural Endpoint in Left Bundle Branch Area Pacing: Conduction System Capture Versus LV Septal Capture LBBAP with mandatory left ventricular conduction system capture (LBBP or LFP), LBBAP with left ventricular septal capture as the accepted procedural endpoint (LVSP) - Bradycardia, Atrioventricular Block | Not applicable | Not yet recruiting | Yonsei University | 300 | 2026-10-01 | 2026-09-04 |
| Erector Spinae Oxygen Saturation and AKI After OPCAB Near-infrared spectroscopy monitoring of erector spinae muscle and renal regional oxygen saturation - Acute Kidney Injury, Coronary Artery Disease | Not yet recruiting | Yonsei University | 138 | 2026-10-01 | 2026-08-12 | |
| Coronary Access After Evolut FX Plus TAVI: Impact of Commissural Alignment and the Large-Cell Frame Design: ACCESS-FX+ Registry Severe Aortic Stenosis | Not yet recruiting | Yonsei University | 122 | 2026-09-29 | 2026-09-10 | |
| JIN-A02 Plus Amivantamab in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Failure JIN-A02 in Combination with Amivantamab - Carcinoma, Non-Small-Cell Lung | Phase 1 | Not yet recruiting | Yonsei University | 36 | 2026-09-28 | 2026-09-02 |
| Associations of Postoperative Hemoglobin With AKI-AKD Trajectories Patients Undergoing Valvular Heart Surgery | Active not recruiting | Yonsei University | 4230 | 2026-09-18 | 2026-10-30 | |
| Autologous Adipose-Derived Stem Cell Injections for Knee Osteoarthritis Autologous Adipose-Derived Mesenchymal Stem Cells (ADMSCs), Cross-linked Hyaluronic Acid (Synovian) - Osteoarthritis, Knee | Not applicable | Recruiting | Yonsei University | 165 | 2026-09-03 | 2026-10-28 |
| OptiCross HD IVUS for Assessing Invasion Depth in Upper Tract Urothelial Carcinoma OptiCross HD Coronary Imaging Catheter - Upper Tract Urothelial Carcinoma | Not applicable | Not yet recruiting | Yonsei University | 15 | 2026-09-01 | 2026-08-07 |
| A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOP Polatuzumab vedotin, Glofitamab - Diffuse Large B-cell Lymphoma | Phase 2 | Not yet recruiting | Yonsei University | 47 | 2026-09-01 | 2026-07-14 |
| Sacituzumab Govitecan and Q901 in Advanced TNBC Sacituzumab govitecan and Q901 - Triple Negative Breast Neoplasms | Phase 2 | Not yet recruiting | Yonsei University | 48 | 2026-09-01 | 2026-08-26 |
Showing 20 of 1452. Sign in to see all of them.
Stomach Neoplasms (66) · Coronary Artery Disease (61) · Atrial Fibrillation (49) · Breast Neoplasms (27) · Stroke (23) · Carcinoma, Non-Small-Cell Lung (22) · Colorectal Neoplasms (19) · Acute Kidney Injury (18) · Pancreatic Neoplasms (18) · Diabetes Mellitus, Type 2 (17) · Lung Neoplasms (17) · Ovarian Neoplasms (16) · Prostatic Neoplasms (16) · Heart Failure (15) · Diabetes Mellitus (14)
Saline Solution (47) · Dexmedetomidine (33) · Propofol (29) · Sodium Chloride (21) · Control Groups (18) · Cisplatin (15) · Remifentanil (15) · Atorvastatin (14) · Docetaxel (13) · pembrolizumab (13) · Paclitaxel (12) · Ropivacaine (11) · Desflurane (10) · Dexamethasone (10) · Ezetimibe (10)
South Korea (1325) · Japan (3) · Singapore (3) · Taiwan (3) · Hong Kong (2) · Australia (1) · China (1) · Indonesia (1) · Switzerland (1) · Thailand (1) · United Kingdom (1) · United States (1)
Yongcheol Kim, MD, PhD (9) · Deog Young Kim (8) · Na Young Kim, MD, PhD (8) · Hye Ryun Kim (7) · Jong Ho Lee, PhD (7) · Gong Je Seong, MD, PhD (6) · Hui-Nam Pak (6) · Joo-Hang Kim, MD (6) · Byeong-Keuk Kim (5) · Hyuk-Jae Chang, MD, PhD (5) · Jong Ho Lee, Ph.D (5) · Jong Ho Lee, Ph.D. (5) · Bon-Nyeo Koo (4) · Sang Hoon Ahn, MD, PhD (4)
PMID 41044734, PMID 20039582, PMID 20590073, PMID 21740078, PMID 24556672, PMID 24812254, PMID 26971404, PMID 30475845, PMID 31141973, PMID 32588238, PMID 41548032, PMID 41697655, PMID 10093981, PMID 10155411, PMID 10434218, PMID 10463984, PMID 11028480, PMID 11096167, PMID 11194105, PMID 11359154, PMID 11401954, PMID 11529208, PMID 11585919, PMID 11822946, PMID 11881867, PMID 12008173, PMID 12378346, PMID 12383306, PMID 12560776, PMID 12616125, PMID 12733140, PMID 1281903, PMID 12821592, PMID 12833452, PMID 14066104, PMID 14524486, PMID 1455316, PMID 14693597, PMID 14693633, PMID 14739848, PMID 14755223, PMID 15082593, PMID 15173543, PMID 15374844, PMID 15385355, PMID 15390043, PMID 15459926, PMID 15507257, PMID 15579771, PMID 15689746
2019 (1)